

Tony Pourmohamad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7834029/publications.pdf>

Version: 2024-02-01

18
papers

560
citations

933447

10
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

972
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	7.0	179
2	Cerebellar Arteriovenous Malformations. <i>Neurosurgery</i> , 2012, 71, 1111-1124.	1.1	87
3	Silent Intralesional Microhemorrhage as a Risk Factor for Brain Arteriovenous Malformation Rupture. <i>Stroke</i> , 2012, 43, 1240-1246.	2.0	78
4	Brain Arteriovenous Malformation Multiplicity Predicts the Diagnosis of Hereditary Hemorrhagic Telangiectasia. <i>Stroke</i> , 2012, 43, 72-78.	2.0	75
5	An Admission Bioclinical Score to Predict 1-Year Outcomes in Patients Undergoing Aneurysm Coiling. <i>Stroke</i> , 2012, 43, 1253-1259.	2.0	28
6	Evaluating Performance of the Spetzler-Martin Supplemented Model in Selecting Patients With Brain Arteriovenous Malformation for Surgery. <i>Stroke</i> , 2012, 43, 2497-2499.	2.0	22
7	Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies. <i>International Journal of Toxicology</i> , 2019, 38, 12-22.	1.2	19
8	Multivariate Stochastic Process Models for Correlated Responses of Mixed Type. <i>Bayesian Analysis</i> , 2016, 11, .	3.0	14
9	Phase I study of the anti- VEGFR^2 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 339-351.	2.3	14
10	Bayesian Optimization Via Barrier Functions. <i>Journal of Computational and Graphical Statistics</i> , 2022, 31, 74-83.	1.7	11
11	Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. <i>NeuroReport</i> , 2012, 23, 627-630.	1.2	10
12	The Statistical Filter Approach to Constrained Optimization. <i>Technometrics</i> , 2020, 62, 303-312.	1.9	10
13	Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. <i>European Journal of Haematology</i> , 2021, 107, 343-353.	2.2	5
14	The Utility of Novel Urinary Biomarkers in Mice for Drug Development Studies. <i>International Journal of Toxicology</i> , 2021, 40, 15-25.	1.2	3
15	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
16	Gaussian Process Modeling for Dissolution Curve Comparisons. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2022, 71, 331-351.	1.0	1
17	Validating Container Closure Integrity with Statistically Based Tests. <i>PDA Journal of Pharmaceutical Science and Technology</i> , 2021, 75, pdajpst.2020.012622.	0.5	0
18	Constrained Optimization. <i>SpringerBriefs in Statistics</i> , 2021, , 69-94.	0.4	0